AUG 7, 2026 · PHASE 3 TRIAL
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
ClinicalTrials.gov
This is a Phase 3 trial registration with no results yet posted; the study is actively recruiting and outcomes are not yet reported.
Reported
Estimated sample size1000
Primary outcome measure 1Progression-free survival (sac-TMT versus T…
Primary outcome measure 2Overall survival (sac-TMT versus TPC), up t…